메뉴 건너뛰기




Volumn 12, Issue 1, 2012, Pages 9-18

Bevacizumab in glioblastoma multiforme

Author keywords

bevacizumab; glioblastoma multiforme; newly diagnosed; recurrent

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CETUXIMAB; ENZASTAURIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FOTEMUSTINE; IRINOTECAN; LOMUSTINE; PANOBINOSTAT; PLACEBO; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; VASCULOTROPIN;

EID: 83455217896     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.179     Document Type: Article
Times cited : (21)

References (84)
  • 1
    • 48249125791 scopus 로고    scopus 로고
    • Malignant gliomas in adults
    • Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 359(5), 492-507 (2008).
    • (2008) N. Engl. J. Med. , vol.359 , Issue.5 , pp. 492-507
    • Wen, P.Y.1    Kesari, S.2
  • 2
    • 20044366163 scopus 로고    scopus 로고
    • Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    • Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
    • (2005) N. Engl. J. Med. , vol.352 , Issue.10 , pp. 987-996
    • Stupp, R.1    Mason, W.P.2    Van Den Bent, M.J.3
  • 3
    • 65349121788 scopus 로고    scopus 로고
    • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial
    • Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
    • (2009) Lancet Oncol. , vol.10 , Issue.5 , pp. 459-466
    • Stupp, R.1    Hegi, M.E.2    Mason, W.P.3
  • 4
    • 78650271417 scopus 로고    scopus 로고
    • Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004
    • doi:10.1093/neuonc/noq030 Epub ahead of print
    • Bauchet L, Mathieu-Daude H, Fabbro-Peray P et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. doi:10.1093/neuonc/noq030 (2010) (Epub ahead of print).
    • (2010) Neuro Oncol.
    • Bauchet, L.1    Mathieu-Daude, H.2    Fabbro-Peray, P.3
  • 5
    • 78651313326 scopus 로고    scopus 로고
    • Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005
    • Fuentes-Raspall R, Vilardell L, Perez-Bueno F et al. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005. J. Neurooncol. 101(1), 117-123 (2011).
    • (2011) J. Neurooncol. , vol.101 , Issue.1 , pp. 117-123
    • Fuentes-Raspall, R.1    Vilardell, L.2    Perez-Bueno, F.3
  • 6
    • 77955002912 scopus 로고    scopus 로고
    • Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: A multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology)
    • Scoccianti S, Magrini SM, Ricardi U et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology). Neurosurgery 67(2), 446-458 (2010).
    • (2010) Neurosurgery , vol.67 , Issue.2 , pp. 446-458
    • Scoccianti, S.1    Magrini, S.M.2    Ricardi, U.3
  • 7
    • 84873081348 scopus 로고    scopus 로고
    • Improved survival time trends for glioblastoma using the SEER 17 population-based registries
    • Koshy M, Vilano JL, Dolecek TA et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J. Clin. Oncol. 29(Suppl.), 2013 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2013
    • Koshy, M.1    Vilano, J.L.2    Dolecek, T.A.3
  • 8
    • 84873085001 scopus 로고    scopus 로고
    • A population-based study of glioblastoma multiforme (GBM) in the new stupp paradigm: Have we improved outcome?
    • Abstract
    • Lwin Z, MacFadden D, Al-Zahrani A et al. A population-based study of glioblastoma multiforme (GBM) in the new stupp paradigm: have we improved outcome? J. Clin. Oncol. 29(Suppl.), 2012 (2011) (Abstract).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2012
    • Lwin, Z.1    MacFadden, D.2    Al-Zahrani, A.3
  • 9
    • 84873093693 scopus 로고    scopus 로고
    • Real-life survival in unselected adult glioblastoma patients: A population-based study
    • Abstract
    • Preusser M, Woehrer A, Zielonke N et al. Real-life survival in unselected adult glioblastoma patients: A population-based study. J. Clin. Oncol. 29(Suppl.), 2014 (2011) (Abstract).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2014
    • Preusser, M.1    Woehrer, A.2    Zielonke, N.3
  • 10
    • 55849130720 scopus 로고    scopus 로고
    • Novel anti-angiogenic therapies for malignant gliomas
    • Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 7(12), 1152-1160 (2008).
    • (2008) Lancet Neurol. , vol.7 , Issue.12 , pp. 1152-1160
    • Norden, A.D.1    Drappatz, J.2    Wen, P.Y.3
  • 12
    • 32944482137 scopus 로고    scopus 로고
    • Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma
    • Abstract
    • Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 7(369) (2005) (Abstract).
    • (2005) Neuro Oncol. , vol.7 , Issue.369
    • Stark-Vance, V.1
  • 13
    • 84873084779 scopus 로고    scopus 로고
    • Bevacizumab (B) with irinotecan (I) in recurrent glioblastoma (Gbm): A national retrospective cohort of the ANOCEF (Association des Neuro-Oncologues D'Expression Francaise) Group
    • Abstract
    • Taillibert S, Hoang-Xuan K, Barrie M et al. Bevacizumab (B) with irinotecan (I) in recurrent glioblastoma (Gbm): a national retrospective cohort of the ANOCEF (Association des Neuro-Oncologues D'Expression Francaise) Group. Neuro Oncol. 12, 52-53 (2010) (Abstract).
    • (2010) Neuro Oncol. , vol.12 , pp. 52-53
    • Taillibert, S.1    Hoang-Xuan, K.2    Barrie, M.3
  • 14
    • 77953872335 scopus 로고    scopus 로고
    • Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
    • Francesconi AB, Dupre S, Matos M et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J. Clin. Neurosci. 17(8), 970-974 (2010).
    • (2010) J. Clin. Neurosci. , vol.17 , Issue.8 , pp. 970-974
    • Francesconi, A.B.1    Dupre, S.2    Matos, M.3
  • 15
    • 84873085777 scopus 로고    scopus 로고
    • Efficacy, safety and pattern of relapse of bevacizumab versus chemotherapy for recurrent glioblastoma multiforme: A McGill University study
    • Abstract
    • Sehebjam S, Ang C, Guiot M et al. Efficacy, safety and pattern of relapse of bevacizumab versus chemotherapy for recurrent glioblastoma multiforme: a McGill University study. Ann. Oncol. 21(Suppl. 8), 1059P (2010) (Abstract).
    • (2010) Ann. Oncol. , vol.21 , Issue.SUPPL. 8 , pp. 1059
    • Sehebjam, S.1    Ang, C.2    Guiot, M.3
  • 16
    • 75049085069 scopus 로고    scopus 로고
    • Salvage therapy with single-agent bevacizumab for recurrent glioblastoma
    • Chamberlain MC, Johnston SK. Salvage therapy with single-agent bevacizumab for recurrent glioblastoma. J. Neurooncol. 96(2), 259-269 (2010).
    • (2010) J. Neurooncol. , vol.96 , Issue.2 , pp. 259-269
    • Chamberlain, M.C.1    Johnston, S.K.2
  • 17
    • 79956135686 scopus 로고    scopus 로고
    • Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
    • Hofer S, Elandt K, Greil R et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol. 50(5), 630-635 (2011).
    • (2011) Acta Oncol. , vol.50 , Issue.5 , pp. 630-635
    • Hofer, S.1    Elandt, K.2    Greil, R.3
  • 18
    • 65249185501 scopus 로고    scopus 로고
    • Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience
    • Nghiemphu PL, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72(14), 1217-1222 (2009).
    • (2009) Neurology , vol.72 , Issue.14 , pp. 1217-1222
    • Nghiemphu, P.L.1    Liu, W.2    Lee, Y.3
  • 19
    • 58149090856 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
    • Poulsen HS, Grunnet K, Sorensen M et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 48(1), 52-58 (2009).
    • (2009) Acta Oncol. , vol.48 , Issue.1 , pp. 52-58
    • Poulsen, H.S.1    Grunnet, K.2    Sorensen, M.3
  • 20
    • 58149456505 scopus 로고    scopus 로고
    • Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
    • Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 91(3), 329-336 (2009).
    • (2009) J. Neurooncol. , vol.91 , Issue.3 , pp. 329-336
    • Zuniga, R.M.1    Torcuator, R.2    Jain, R.3
  • 21
    • 79958217698 scopus 로고    scopus 로고
    • Recurrent spinal cord glioblastoma: Salvage therapy with bevacizumab
    • Chamberlain MC, Johnston SK. Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab. J. Neurooncol. 102(3), 427-432 (2011).
    • (2011) J. Neurooncol. , vol.102 , Issue.3 , pp. 427-432
    • Chamberlain, M.C.1    Johnston, S.K.2
  • 22
    • 36049037819 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    • Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.30 , pp. 4722-4729
    • Vredenburgh, J.J.1    Desjardins, A.2    Herndon, J.E.3
  • 23
    • 71649094684 scopus 로고    scopus 로고
    • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: A Phase II study
    • Reardon DA, Desjardins A, Vredenburgh JJ et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a Phase II study. Br. J. Cancer 101(12), 1986-1994 (2009).
    • (2009) Br. J. Cancer , vol.101 , Issue.12 , pp. 1986-1994
    • Reardon, D.A.1    Desjardins, A.2    Vredenburgh, J.J.3
  • 24
    • 80053142607 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology)
    • Abstract
    • Soffietti R, Trevisan E, Ruda R et al. Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: final results of a multicenter study of AINO (Italian Association of Neuro-oncology). J. Clin. Oncol. 29(Suppl.), 2027 (2011) (Abstract).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2027
    • Soffietti, R.1    Trevisan, E.2    Ruda, R.3
  • 25
    • 84951208522 scopus 로고    scopus 로고
    • Bevacizumab and fotemustine as salvage therapy in recurrent glioblastoma: A Phase II multicenter Italian study
    • Abstract
    • Trevisan E, Ruda R, Picco E et al. Bevacizumab and fotemustine as salvage therapy in recurrent glioblastoma: a Phase II multicenter Italian study. Neuro Oncol. 12(iii), P117 (2010) (Abstract).
    • (2010) Neuro Oncol. , vol.12 , Issue.3
    • Trevisan, E.1    Ruda, R.2    Picco, E.3
  • 26
    • 83455209534 scopus 로고    scopus 로고
    • Bevacizumab in combination with irinotecan or temozolomide in recurrent glioblastoma: Efficacy and safety results from a pilot study
    • Abstract
    • Kobyakov G, Absalyamova O, Amanov R. Bevacizumab in combination with irinotecan or temozolomide in recurrent glioblastoma: efficacy and safety results from a pilot study. Neuro Oncol. 12, 54 (2010) (Abstract).
    • (2010) Neuro Oncol. , vol.12 , pp. 54
    • Kobyakov, G.1    Absalyamova, O.2    Amanov, R.3
  • 27
    • 84951013721 scopus 로고    scopus 로고
    • Updated results of a Phase II trial of bevacizumab and irinotecan in relapsed high grade glioma
    • Abstract
    • Keyrouz VR, Elias EF, Chahine GY, Comair YG, Dimassi H, Kamar FG. Updated results of a Phase II trial of bevacizumab and irinotecan in relapsed high grade glioma. Neuro Oncol. 12(iii), P108 (2010) (Abstract).
    • (2010) Neuro Oncol. , vol.12 , Issue.3
    • Keyrouz, V.R.1    Elias, E.F.2    Chahine, G.Y.3    Comair, Y.G.4    Dimassi, H.5    Kamar, F.G.6
  • 28
    • 77955242817 scopus 로고    scopus 로고
    • Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
    • Verhoeff JJC, Lavini C, van Linde ME et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann. Oncol. 21(8), 1723-1727 (2010).
    • (2010) Ann. Oncol. , vol.21 , Issue.8 , pp. 1723-1727
    • Verhoeff, J.J.C.1    Lavini, C.2    Van Linde, M.E.3
  • 29
    • 59949083263 scopus 로고    scopus 로고
    • Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
    • Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.5 , pp. 740-745
    • Kreisl, T.N.1    Kim, L.2    Moore, K.3
  • 30
    • 78449274656 scopus 로고    scopus 로고
    • A Phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
    • Raizer JJ, Grimm S, Chamberlain MC et al. A Phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22), 5297-5305 (2010).
    • (2010) Cancer , vol.116 , Issue.22 , pp. 5297-5305
    • Raizer, J.J.1    Grimm, S.2    Chamberlain, M.C.3
  • 31
    • 80052609763 scopus 로고    scopus 로고
    • Long-term survival from the initial trial of bevacizumab and irinotecan
    • Abstract
    • Desjardins A, Vredenburgh JJ, Reardon DA et al. Long-term survival from the initial trial of bevacizumab and irinotecan. J. Clin. Oncol. 28(15s), 2045 (2010) (Abstract).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.15 , pp. 2045
    • Desjardins, A.1    Vredenburgh, J.J.2    Reardon, D.A.3
  • 32
    • 84873096007 scopus 로고    scopus 로고
    • Results of treatment pediatric recurrent high grade glioma with combination of bevacizumab and irinotecan
    • Abstract
    • Geludkova OG, Borodina ID, Melikian AG et al. Results of treatment pediatric recurrent high grade glioma with combination of bevacizumab and irinotecan. Neuro Oncol. 12(iii), P131 (2010) (Abstract).
    • (2010) Neuro Oncol. , vol.12 , Issue.3
    • Geludkova, O.G.1    Borodina, I.D.2    Melikian, A.G.3
  • 33
    • 77954578108 scopus 로고    scopus 로고
    • Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A pediatric brain tumor consortium study
    • Gururangan S, Chi SN, Poussaint TY et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J. Clin. Oncol. 28(18), 3069-3075 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.18 , pp. 3069-3075
    • Gururangan, S.1    Chi, S.N.2    Poussaint, T.Y.3
  • 34
    • 70350461699 scopus 로고    scopus 로고
    • Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
    • Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , Issue.28 , pp. 4733-4740
    • Friedman, H.S.1    Prados, M.D.2    Wen, P.Y.3
  • 35
    • 77956666382 scopus 로고    scopus 로고
    • Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study
    • Abstract
    • Cloughesy TF, Vredenburgh JJ, Day B, Das A, Friedland HS. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J. Clin. Oncol. 28(15s), 2008 (2010) (Abstract).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.15 S , pp. 2008
    • Cloughesy, T.F.1    Vredenburgh, J.J.2    Day, B.3    Das, A.4    Friedland, H.S.5
  • 36
    • 79951632471 scopus 로고    scopus 로고
    • Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
    • Prados M, Cloughesy T, Samant M et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 13(1), 143-151 (2011).
    • (2011) Neuro Oncol. , vol.13 , Issue.1 , pp. 143-151
    • Prados, M.1    Cloughesy, T.2    Samant, M.3
  • 37
    • 78650990754 scopus 로고    scopus 로고
    • Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study
    • Vredenburgh JJ, Cloughesy T, Samant M et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15(12), 1329-1334 (2010).
    • (2010) Oncologist , vol.15 , Issue.12 , pp. 1329-1334
    • Vredenburgh, J.J.1    Cloughesy, T.2    Samant, M.3
  • 38
    • 79952140602 scopus 로고    scopus 로고
    • Rtog 0625: A randomized Phase II trial of bevacizumab with either irinotecan (Cpt) or dose-dense temozolomide (Tmz) in recurrent glioblastoma (Gbm)
    • Abstract
    • Gilbert MR, Wang MH, Aldape K et al. Rtog 0625: a randomized Phase II trial of bevacizumab with either irinotecan (Cpt) or dose-dense temozolomide (Tmz) in recurrent glioblastoma (Gbm). Neuro Oncol. 12, 39 (2010) (Abstract).
    • (2010) Neuro Oncol. , vol.12 , pp. 39
    • Gilbert, M.R.1    Wang, M.H.2    Aldape, K.3
  • 39
    • 84873093206 scopus 로고    scopus 로고
    • Toxicity of combined bevacizumab-lomustine treatment in patients with recurrent glioblastoma (Gbm): Report from a randomized Phase II study
    • Abstract
    • van den Bent M, Taal W, Sleijfer S et al. Toxicity of combined bevacizumab-lomustine treatment in patients with recurrent glioblastoma (Gbm): report from a randomized Phase II study. Neuro Oncol. 12, 42 (2010) (Abstract).
    • (2010) Neuro Oncol. , vol.12 , pp. 42
    • Van Den Bent, M.1    Taal, W.2    Sleijfer, S.3
  • 40
    • 83455167756 scopus 로고    scopus 로고
    • Bevacizumab for recurrent glioblastoma multiforme: A meta-analysis
    • Abstract
    • Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. Ann. Neurol. 68(4), S61-S62 (2010) (Abstract).
    • (2010) Ann. Neurol. , vol.68 , Issue.4
    • Wong, E.T.1    Gautam, S.2    Malchow, C.3    Lun, M.4    Pan, E.5    Brem, S.6
  • 41
    • 83055181490 scopus 로고    scopus 로고
    • Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients
    • doi:10.1007/s11060-011-0642-1 Epub ahead of print
    • Norden AD, Bartolomeo J, Tanaka S et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J. Neurooncol. doi:10.1007/s11060-011-0642-1 (2011) (Epub ahead of print).
    • (2011) J. Neurooncol.
    • Norden, A.D.1    Bartolomeo, J.2    Tanaka, S.3
  • 42
    • 79957976065 scopus 로고    scopus 로고
    • Impact of bevacizumab chemotherapy on craniotomy wound healing
    • Clark AJ, Butowski NA, Chang SM et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J. Neurosurg. 114(6), 1609-1616 (2011).
    • (2011) J. Neurosurg. , vol.114 , Issue.6 , pp. 1609-1616
    • Clark, A.J.1    Butowski, N.A.2    Chang, S.M.3
  • 43
    • 77954991899 scopus 로고    scopus 로고
    • Optic neuropathy in patients with glioblastoma receiving bevacizumab
    • Chamberlain MC, Raizer J. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 75(3), 289-290 (2010).
    • (2010) Neurology , vol.75 , Issue.3 , pp. 289-290
    • Chamberlain, M.C.1    Raizer, J.2
  • 44
    • 73349106835 scopus 로고    scopus 로고
    • Optic neuropathy in patients with glioblastoma receiving bevacizumab
    • Sherman JH, Aregawi DG, Lai A et al. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 73(22), 1924-1926 (2009).
    • (2009) Neurology , vol.73 , Issue.22 , pp. 1924-1926
    • Sherman, J.H.1    Aregawi, D.G.2    Lai, A.3
  • 45
    • 77954720781 scopus 로고    scopus 로고
    • Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    • Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817-2823 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.17 , pp. 2817-2823
    • Batchelor, T.T.1    Duda, D.G.2    Di Tomaso, E.3
  • 46
    • 79951957939 scopus 로고    scopus 로고
    • A Phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients
    • Abstract
    • Batchelor TT, Mulholland P, Neyns B, et al. A Phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. Ann. Oncol. 21(Suppl. 8), LBA7 (2010) (Abstract).
    • (2010) Ann. Oncol. , vol.21 , Issue.SUPPL. 8
    • Batchelor, T.T.1    Mulholland, P.2    Neyns, B.3
  • 47
    • 77949891455 scopus 로고    scopus 로고
    • Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma
    • Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28(7), 1168-1174 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.7 , pp. 1168-1174
    • Wick, W.1    Puduvalli, V.K.2    Chamberlain, M.C.3
  • 48
    • 34447285771 scopus 로고    scopus 로고
    • Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium Phase i and II clinical trials
    • Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium Phase I and II clinical trials. J. Clin. Oncol. 25(18), 2601-2606 (2007).
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18 , pp. 2601-2606
    • Carson, K.A.1    Grossman, S.A.2    Fisher, J.D.3    Shaw, E.G.4
  • 49
    • 84873076918 scopus 로고    scopus 로고
    • Bevacizumab-based therapy recurrent malignant glioma: Correlation between serum VEGF and response to treatment
    • Pace A, Conti L, Russillo M et al. Bevacizumab-based therapy recurrent malignant glioma: correlation between serum VEGF and response to treatment. Neuro Oncol. 12, 33-34 (2010).
    • (2010) Neuro Oncol. , vol.12 , pp. 33-34
    • Pace, A.1    Conti, L.2    Russillo, M.3
  • 50
    • 84856008240 scopus 로고    scopus 로고
    • The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM)
    • Abstract
    • Nangia CS, Wang D, Scarpace L, Schultz L, Khanshour A, Mikkelsen T. The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM). J. Clin. Oncol. 29(Suppl.), 2021 (2011) (Abstract).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2021
    • Nangia, C.S.1    Wang, D.2    Scarpace, L.3    Schultz, L.4    Khanshour, A.5    Mikkelsen, T.6
  • 51
    • 77955653792 scopus 로고    scopus 로고
    • Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab
    • Abstract
    • Wu J, Gilbert MR, de Groot JF, Yung WA, Puduvalli VK. Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab. J. Clin. Oncol. 28(15s), 2024 (2010) (Abstract).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.15 , pp. 2024
    • Wu, J.1    Gilbert, M.R.2    De Groot, J.F.3    Yung, W.A.4    Puduvalli, V.K.5
  • 52
    • 80052001722 scopus 로고    scopus 로고
    • Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma
    • Gupta A, Young RJ, Karimi S, et al. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am. J. Neuroradiol. 32(7), 1301-1306 (2011).
    • (2011) AJNR Am. J. Neuroradiol. , vol.32 , Issue.7 , pp. 1301-1306
    • Gupta, A.1    Young, R.J.2    Karimi, S.3
  • 53
    • 77949911509 scopus 로고    scopus 로고
    • Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab
    • Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J. Clin. Oncol. 28(6), e91-e93 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.6
    • Gerstner, E.R.1    Frosch, M.P.2    Batchelor, T.T.3
  • 54
    • 36048955738 scopus 로고    scopus 로고
    • Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study
    • Chen W, Delaloye S, Silverman DHS et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25, 4714-4721 (2007).
    • (2007) J. Clin. Oncol. , vol.25 , pp. 4714-4721
    • Chen, W.1    Delaloye, S.2    Silverman, D.H.S.3
  • 55
    • 67649092660 scopus 로고    scopus 로고
    • Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
    • Quant EC, Norden AD, Drappatz J et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 11(5), 550-555 (2009).
    • (2009) Neuro Oncol. , vol.11 , Issue.5 , pp. 550-555
    • Quant, E.C.1    Norden, A.D.2    Drappatz, J.3
  • 56
    • 70350142397 scopus 로고    scopus 로고
    • Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
    • Iwamoto FM, Abrey LE, Beal K et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73(15), 1200-1206 (2009).
    • (2009) Neurology , vol.73 , Issue.15 , pp. 1200-1206
    • Iwamoto, F.M.1    Abrey, L.E.2    Beal, K.3
  • 57
    • 77956061453 scopus 로고    scopus 로고
    • Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
    • Zuniga RM, Torcuator R, Jain R et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neurooncol. 99(2), 237-242 (2010).
    • (2010) J. Neurooncol. , vol.99 , Issue.2 , pp. 237-242
    • Zuniga, R.M.1    Torcuator, R.2    Jain, R.3
  • 58
    • 79959812904 scopus 로고    scopus 로고
    • Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
    • Reardon DA, Desjardins A, Peters K et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J. Neurooncol. 103(2), 371-379 (2011).
    • (2011) J. Neurooncol. , vol.103 , Issue.2 , pp. 371-379
    • Reardon, D.A.1    Desjardins, A.2    Peters, K.3
  • 59
    • 80053145837 scopus 로고    scopus 로고
    • Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials
    • Abstract
    • Reardon DA, Vredenburgh JJ, Desjardins A et al. Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. J. Clin. Oncol. 29(Suppl.), 2030 (2011) (Abstract).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2030
    • Reardon, D.A.1    Vredenburgh, J.J.2    Desjardins, A.3
  • 60
    • 79953282797 scopus 로고    scopus 로고
    • Bevacizumab does not increase the risk of remote relapse in malignant glioma
    • Wick A, Dörner N, Schäfer N et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann. Neurol. 69(3), 586-592 (2011).
    • (2011) Ann. Neurol. , vol.69 , Issue.3 , pp. 586-592
    • Wick, A.1    Dörner, N.2    Schäfer, N.3
  • 61
    • 80053601205 scopus 로고    scopus 로고
    • Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma
    • Abstract
    • Cuneo KC, Cabrera AR, Sampson JH et al. Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. J. Clin. Oncol. 29(Suppl.), 2082 (2011) (Abstract).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2082
    • Cuneo, K.C.1    Cabrera, A.R.2    Sampson, J.H.3
  • 62
    • 68649114787 scopus 로고    scopus 로고
    • Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas
    • Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 75(1), 156-163 (2009).
    • (2009) Int. J. Radiat. Oncol. Biol. Phys. , vol.75 , Issue.1 , pp. 156-163
    • Gutin, P.H.1    Iwamoto, F.M.2    Beal, K.3
  • 63
    • 78650102866 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
    • Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 12(12), 1300-1310 (2010).
    • (2010) Neuro Oncol. , vol.12 , Issue.12 , pp. 1300-1310
    • Sathornsumetee, S.1    Desjardins, A.2    Vredenburgh, J.J.3
  • 64
    • 77954748580 scopus 로고    scopus 로고
    • Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A Phase II trial
    • Hasselbalch B, Lassen U, Hansen S et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a Phase II trial. Neuro Oncol. 12(5), 508-516 (2010).
    • (2010) Neuro Oncol. , vol.12 , Issue.5 , pp. 508-516
    • Hasselbalch, B.1    Lassen, U.2    Hansen, S.3
  • 65
    • 84873089729 scopus 로고    scopus 로고
    • Phase II trial of enzastaurin (Enz) with bevacizumab (Bv) in adults with recurrent glioblastoma (Gem)
    • Abstract
    • Moustakas A, Iwamoto FM, Kreisl TN et al. Phase II trial of enzastaurin (Enz) with bevacizumab (Bv) in adults with recurrent glioblastoma (Gem). Neuro Oncol. 12, 37 (2010) (Abstract).
    • (2010) Neuro Oncol. , vol.12 , pp. 37
    • Moustakas, A.1    Iwamoto, F.M.2    Kreisl, T.N.3
  • 66
    • 84866721138 scopus 로고    scopus 로고
    • Phase II study of bevacizumab and temsirolimus in patients with progressive glioblastoma multiforme after prior bevacizumab treatment
    • Gaziel TB, Soerensen M, Hasselbalch B, Poulsen HS, Lassen U. Phase II study of bevacizumab and temsirolimus in patients with progressive glioblastoma multiforme after prior bevacizumab treatment. Neuro Oncol. 12, 40 (2010).
    • (2010) Neuro Oncol. , vol.12 , pp. 40
    • Gaziel, T.B.1    Soerensen, M.2    Hasselbalch, B.3    Poulsen, H.S.4    Lassen, U.5
  • 67
    • 83455209525 scopus 로고    scopus 로고
    • Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma
    • Abstract
    • Bota DA, Eroglu Z, Reardon DA et al. Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. J. Clin. Oncol. 29(Suppl.), 2056 (2011) (Abstract).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2056
    • Bota, D.A.1    Eroglu, Z.2    Reardon, D.A.3
  • 68
    • 84873077741 scopus 로고    scopus 로고
    • NCCTG Phase II trial of bevacizumab in combination with sorafenib in recurrent GBM
    • Galanis E, Jaeckle KA, Anderson SK et al. NCCTG Phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. J. Clin. Oncol. 28(15s), 2018 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.15 , pp. 2018
    • Galanis, E.1    Jaeckle, K.A.2    Anderson, S.K.3
  • 69
    • 83455209522 scopus 로고    scopus 로고
    • A Phase i trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG)
    • Abstract
    • Drappatz J, Raizer JJ, Schiff D et al. A Phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). J. Clin. Oncol. 29(Suppl.), 2050 (2011) (Abstract).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2050
    • Drappatz, J.1    Raizer, J.J.2    Schiff, D.3
  • 70
    • 84873096930 scopus 로고    scopus 로고
    • Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma
    • Abstract
    • Lou E, Reardon DA, Peters K et al. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. J. Clin. Oncol. 29(Suppl.), 2055 (2011) (Abstract).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2055
    • Lou, E.1    Reardon, D.A.2    Peters, K.3
  • 71
    • 80053141888 scopus 로고    scopus 로고
    • Randomized multicenter Phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Interim results of the TEMAVIR study from the ANOCEF group
    • Abstract
    • Chauffert B, Feuvet L, Bonnetain F et al. Randomized multicenter Phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: interim results of the TEMAVIR study from the ANOCEF group. J. Clin. Oncol. 29(Suppl.), 2029 (2011) (Abstract).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2029
    • Chauffert, B.1    Feuvet, L.2    Bonnetain, F.3
  • 72
    • 78751705500 scopus 로고    scopus 로고
    • First-line therapy with bevacizumab and irinotecan versus bevacizumab and temozolomide and delayed concomitant radiotherapy in newly diagnosed primary glioblastoma multiforme: Early results from a randomized Phase II study
    • Abstract
    • Hofland KF, Poulsen HS, Sorensen MP et al. First-line therapy with bevacizumab and irinotecan versus bevacizumab and temozolomide and delayed concomitant radiotherapy in newly diagnosed primary glioblastoma multiforme: early results from a randomized Phase II study. Neuro Oncol. 11(5), 620 (2009) (Abstract).
    • (2009) Neuro Oncol. , vol.11 , Issue.5 , pp. 620
    • Hofland, K.F.1    Poulsen, H.S.2    Sorensen, M.P.3
  • 73
    • 84873086814 scopus 로고    scopus 로고
    • The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide and irinotecan for newly diagnosed glioblastoma
    • Vredenburgh JJ, Desjardins A, Reardon DA et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide and irinotecan for newly diagnosed glioblastoma. Clin.Cancer Res. 69(3), 586-592 (2011).
    • (2011) Clin. Cancer Res. , vol.69 , Issue.3 , pp. 586-592
    • Vredenburgh, J.J.1    Desjardins, A.2    Reardon, D.A.3
  • 74
    • 79951984402 scopus 로고    scopus 로고
    • Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
    • Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29(2), 142-148 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.2 , pp. 142-148
    • Lai, A.1    Tran, A.2    Nghiemphu, P.L.3
  • 75
    • 80053146368 scopus 로고    scopus 로고
    • Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)
    • Abstract
    • Omuro AM, Beal K, Karimi S et al. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). J. Clin. Oncol. 29(Suppl.), 2028 (2011) (Abstract).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL. , pp. 2028
    • Omuro, A.M.1    Beal, K.2    Karimi, S.3
  • 76
    • 79958210803 scopus 로고    scopus 로고
    • AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
    • Chinot OL, de La Motte Rouge T, Moore N et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther. 28(4), 334-340 (2011).
    • (2011) Adv. Ther. , vol.28 , Issue.4 , pp. 334-340
    • Chinot, O.L.1    De La Motte Rouge, T.2    Moore, N.3
  • 77
    • 79960606592 scopus 로고    scopus 로고
    • Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM)
    • Abstract
    • Shih KC, Spikel DR, Burris HA III, Brown RH, Shepard GC, Hainsworth JD. Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM). J. Clin. Oncol. 28(15s), 2075 (2010) (Abstract).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.15 , pp. 2075
    • Shih, K.C.1    Spikel, D.R.2    Burris Iii, H.A.3    Brown, R.H.4    Shepard, G.C.5    Hainsworth, J.D.6
  • 78
    • 75449088610 scopus 로고    scopus 로고
    • FDA Drug Approval Summary: Bevacizumab (Avastin®) as treatment of recurrent glioblastoma multiforme
    • Cohen MH, Shen YL, Keegan P, Pazdur R. FDA Drug Approval Summary: bevacizumab (Avastin®) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11), 1131-1138 (2009).
    • (2009) Oncologist , vol.14 , Issue.11 , pp. 1131-1138
    • Cohen, M.H.1    Shen, Y.L.2    Keegan, P.3    Pazdur, R.4
  • 79
    • 79958206587 scopus 로고    scopus 로고
    • Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: A good idea or a grave error?
    • Balana C, Etxaniz O, Buges C, Martinez A. Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error? Clin. Transl. Oncol. 13(3), 209-210 (2011).
    • (2011) Clin. Transl. Oncol. , vol.13 , Issue.3 , pp. 209-210
    • Balana, C.1    Etxaniz, O.2    Buges, C.3    Martinez, A.4
  • 81
    • 84873097055 scopus 로고    scopus 로고
    • European Medicines Agency Accessed 24 November 2011)
    • European Medicines Agency. Product information Avastin. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/ 000582/WC500029271.pdf (Accessed 24 November 2011)
    • Product Information Avastin
  • 82
    • 76949086699 scopus 로고    scopus 로고
    • National Cancer Institute Accessed 11 July 2011
    • National Cancer Institute. Clinical Trials Homepage. www.cancer.gov/ clinicaltrials (Accessed 11 July 2011)
    • Clinical Trials Homepage
  • 83
    • 84873090562 scopus 로고    scopus 로고
    • US FDA Department of Health and Human Services Accessed 30 June 2011
    • US FDA. Department of Health and Human Services. www.accessdata.fda.gov/ drugsatfda-docs/appletter/2009/125085s0169ltr.pdf (Accessed 30 June 2011)
  • 84
    • 84873095213 scopus 로고    scopus 로고
    • European Medicines Agency Accessed 24 November 2011
    • European Medicines Agency. Avastin: refusal registration glioblastoma. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/ human/000582/WC500075000.pdf (Accessed 24 November 2011)
    • Avastin: Refusal Registration Glioblastoma


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.